Novartis AG $NVS Shares Purchased by May Hill Capital LLC

May Hill Capital LLC raised its holdings in Novartis AG (NYSE:NVS) by 49.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,274 shares of the company’s stock after buying an additional 2,084 shares during the period. May Hill Capital LLC’s holdings in Novartis were worth $759,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Brighton Jones LLC lifted its stake in Novartis by 76.5% during the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after purchasing an additional 2,666 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Novartis by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 6,524 shares of the company’s stock worth $727,000 after buying an additional 1,500 shares during the last quarter. Spire Wealth Management boosted its holdings in shares of Novartis by 17.2% in the 1st quarter. Spire Wealth Management now owns 3,032 shares of the company’s stock valued at $338,000 after buying an additional 446 shares in the last quarter. Bessemer Group Inc. boosted its holdings in shares of Novartis by 10.9% in the 1st quarter. Bessemer Group Inc. now owns 11,289 shares of the company’s stock valued at $1,258,000 after buying an additional 1,105 shares in the last quarter. Finally, Western Wealth Management LLC purchased a new position in shares of Novartis in the 1st quarter valued at $216,000. 13.12% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVS has been the subject of a number of research reports. The Goldman Sachs Group reissued a “sell” rating and issued a $118.00 price target (down from $119.00) on shares of Novartis in a research report on Friday, September 12th. HC Wainwright cut Novartis to a “neutral” rating in a research report on Monday. Wall Street Zen upgraded Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a research note on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Novartis in a report on Thursday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $120.33.

Novartis Stock Performance

Shares of NVS stock opened at $129.12 on Tuesday. The stock’s 50-day moving average price is $127.66 and its 200 day moving average price is $119.78. The company has a quick ratio of 0.62, a current ratio of 0.82 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $272.76 billion, a PE ratio of 18.79, a price-to-earnings-growth ratio of 1.82 and a beta of 0.64. Novartis AG has a 52-week low of $96.06 and a 52-week high of $133.55.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.